BSL Ltd. News and Updates

Keep track of all breaking news on BSL Ltd. from all sources in a single place.

19 Dec 2024, 06:51AM

169.52

0.87%

8 deaths from unknown illness in J&K's Rajouri, Centre sets up experts team

Business Standard

The death toll from an unknown illness in Jammu and Kashmir's Rajouri district has risen to eight, with another child succumbing to the mysterious disease in a hospital here on Wednesday, prompting authorities to set up a central team of experts to assist in investigating the cases and fatalities in the affected village. A Biosafety level 3 (BSL-3) mobile laboratory has been dispatched to Rajouri to expedite testing and identify the illness, officials said Twelve-year-old Ashfaq Ahmed, son of Mohammad Rafiq, passed away after being hospitalised at the Government Medical College (GMC) Jammu for six days, officials said. He was earlier referred to Chandigarh for treatment but could not survive, officials said. Ashfaq's younger siblingsseven-year-old Ishtiyaq and five-year-old Naziadied last Thursday. With the death of Ashfaq, the number of fatalities in Badhaal village of Kotranka tehsil has reached eight. All the deceased belonged to two families from the same village. Deputy...

BSL Ltd. is trading below all available SMAs

BSL Ltd.

07 Nov 2024

169.52

0.87%

Fund review: Aditya BSL Frontline Equity

Business Standard

Fund review: Aditya BSL Frontline Equity

BSL Ltd. has lost -23.42% in the last 6 Months

BSL Ltd.

08 Aug 2024

169.52

0.87%

Fund review: Aditya BSL Short Term Fund

Business Standard

Fund review: Aditya BSL Short Term Fund

BSL Ltd. is trading below all available SMAs

BSL Ltd.

07 Nov 2023

169.52

0.87%

BSL Standalone September 2023 Net Sales at Rs 178.69 crore, up 34.63% Y-o-Y

Moneycontrol

BSL Ltd. has lost -29.98% in the last 3 Months

BSL Ltd.

08 Jun 2023

169.52

0.87%

Fund pick: Aditya BSL Medium Term Plan

Business Standard

Fund pick of Aditya BSL Medium Term Plan

BSL Ltd. is trading below all available SMAs

BSL Ltd.

26 May 2023

169.52

0.87%

Fund pick: Aditya BSL Dynamic Bond Fund

Business Standard

Fund pick of Aditya BSL Dynamic Bond Fund

BSL Ltd. has lost -29.98% in the last 3 Months

BSL Ltd.

23 Dec 2022

169.52

0.87%

Fund pick: Aditya BSL Medium Term Plan

Business Standard

Fund pick of Aditya BSL Medium Term Plan

BSL Ltd. has lost -29.98% in the last 3 Months

BSL Ltd.

18 Dec 2022, 03:46PM

169.52

0.87%

BSL Ltd to invest 200 cr on setting up cotton spinning unit and modernisation of existing facilities

Business Line

The company is looking to grow its revenues by 20% to touch 500-550 cr by the end of this fiscal

BSL Ltd. has lost -23.42% in the last 6 Months

BSL Ltd.

30 Aug 2022

169.52

0.87%

IISc's SARS-CoV-2 virus-like particle may lead to new Covid-19 vaccine

Business Standard

Scientists at the Indian Institute of Science (IISc) Bangalore have developed and tested a novel SARS-CoV-2 virus-like particle that can potentially be developed into a COVID-19 vaccine candidate. To study the SARS-CoV-2 virus, the researchers need to isolate the virus from the samples, create multiple copies of it, and analyse its transmissibility and efficiency at entering living cells. However, working with such a highly infectious virus is dangerous and requires a Bio Safety Level-3 (BSL-3) lab, only a handful of which across the country are equipped to handle such viruses. To address this problem, the team developed and tested a novel virus-like particle (VLP) -- a non-infectious nanoscale molecule that resembles and behaves like the SARS-CoV-2 virus but does not contain its native genetic material. Such VLPs can not only be used to safely study the effect of mutations that may arise in SARS-CoV-2, but can also potentially be developed into a vaccine candidate that can trigger